About Receptor-type tyrosine-protein phosphatase delta
Receptor-type tyrosine-protein phosphatase delta (PTPRD) is a protein
from Homo sapiens identified by UniProt accession
P23468, 1912 residues long.
MolForge cross-references it against 0 known binders and
400 disease associations.
Target properties
| Protein name | Receptor-type tyrosine-protein phosphatase delta |
|---|
| UniProt accession | P23468 |
|---|
| Gene | PTPRD |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1912 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (400)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.45
- chronotype measurement · score 0.42
- gut microbiome measurement · score 0.38
- retinal nerve fibre layer thickness measurement · score 0.33
- adolescent idiopathic scoliosis · score 0.33
- multiple sclerosis · score 0.33
- Alzheimer disease · score 0.33
- lysosomal storage disease · score 0.33
- Parkinson disease · score 0.33
- urate measurement · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P23468-F1 | alphafold | PREDICTED | 82.76 | — |
Amino-acid sequence (1912 residues)
MVHVARLLLL LLTFFLRTDA ETPPRFTRTP VDQTGVSGGV ASFICQATGD PRPKIVWNKK GKKVSNQRFE VIEFDDGSGS VLRIQPLRTP RDEAIYECVA SNNVGEISVS TRLTVLREDQ IPRGFPTIDM GPQLKVVERT RTATMLCAAS GNPDPEITWF KDFLPVDTSN NNGRIKQLRS ESIGGTPIRG ALQIEQSEES DQGKYECVAT NSAGTRYSAP ANLYVRELRE VRRVPPRFSI PPTNHEIMPG GSVNITCVAV GSPMPYVKWM LGAEDLTPED DMPIGRNVLE LNDVRQSANY TCVAMSTLGV IEAIAQITVK ALPKPPGTPV VTESTATSIT LTWDSGNPEP VSYYIIQHKP KNSEELYKEI DGVATTRYSV AGLSPYSDYE FRVVAVNNIG RGPPSEPVLT QTSEQAPSSA PRDVQARMLS STTILVQWKE PEEPNGQIQG YRVYYTMDPT QHVNNWMKHN VADSQITTIG NLVPQKTYSV KVLAFTSIGD GPLSSDIQVI TQTGVPGQPL NFKAEPESET SILLSWTPPR SDTIANYELV YKDGEHGEEQ RITIEPGTSY RLQGLKPNSL YYFRLAARSP QGLGASTAEI SARTMQSKPS APPQDISCTS PSSTSILVSW QPPPVEKQNG IITEYSIKYT AVDGEDDKPH EILGIPSDTT KYLLEQLEKW TEYRITVTAH TDVGPGPESL SVLIRTNEDV PSGPPRKVEV EAVNSTSVKV SWRSPVPNKQ HGQIRGYQVH YVRMENGEPK GQPMLKDVML ADAQWEFDDT TEHDMIISGL QPETSYSLTV TAYTTKGDGA RSKPKLVSTT GAVPGKPRLV INHTQMNTAL IQWHPPVDTF GPLQGYRLKF GRKDMEPLTT LEFSEKEDHF TATDIHKGAS YVFRLSARNK VGFGEEMVKE ISIPEEVPTG FPQNLHSEGT TSTSVQLSWQ PPVLAERNGI ITKYTLLYRD INIPLLPMEQ LIVPADTTMT LTGLKPDTTY DVKVRAHTSK GPGPYSPSVQ FRTLPVDQVF AKNFHVKAVM KTSVLLSWEI PENYNSAMPF KILYDDGKMV EEVDGRATQK LIVNLKPEKS YSFVLTNRGN SAGGLQHRVT AKTAPDVLRT KPAFIGKTNL DGMITVQLPE VPANENIKGY YIIIVPLKKS RGKFIKPWES PDEMELDELL KEISRKRRSI RYGREVELKP YIAAHFDVLP TEFTLGDDKH YGGFTNKQLQ SGQEYVFFVL AVMEHAESKM YATSPYSDPV VSMDLDPQPI TDEEEGLIWV VGPVLAVVFI ICIVIAILLY KRKRAESDSR KSSIPNNKEI PSHHPTDPVE LRRLNFQTPG MASHPPIPIL ELADHIERLK ANDNLKFSQE YESIDPGQQF TWEHSNLEVN KPKNRYANVI AYDHSRVLLS AIEGIPGSDY VNANYIDGYR KQNAYIATQG SLPETFGDFW RMIWEQRSAT VVMMTKLEER SRVKCDQYWP SRGTETHGLV QVTLLDTVEL ATYCVRTFAL YKNGSSEKRE VRQFQFTAWP DHGVPEHPTP FLAFLRRVKT CNPPDAGPMV VHCSAGVGRT GCFIVIDAML ERIKHEKTVD IYGHVTLMRA QRNYMVQTED QYIFIHDALL EAVTCGNTEV PARNLYAYIQ KLTQIETGEN VTGMELEFKR LASSKAHTSR FISANLPCNK FKNRLVNIMP YESTRVCLQP IRGVEGSDYI NASFIDGYRQ QKAYIATQGP LAETTEDFWR MLWEHNSTIV VMLTKLREMG REKCHQYWPA ERSARYQYFV VDPMAEYNMP QYILREFKVT DARDGQSRTV RQFQFTDWPE QGVPKSGEGF IDFIGQVHKT KEQFGQDGPI SVHCSAGVGR TGVFITLSIV LERMRYEGVV DIFQTVKMLR TQRPAMVQTE DQYQFSYRAA LEYLGSFDHY AT
Explore Receptor-type tyrosine-protein phosphatase delta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets